SciCombinator

Discover the most talked about and latest scientific content & concepts.

Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden

OPEN The New England journal of medicine | 17 Apr 2018

MD Hellmann, TE Ciuleanu, A Pluzanski, JS Lee, GA Otterson, C Audigier-Valette, E Minenza, H Linardou, S Burgers, P Salman, H Borghaei, SS Ramalingam, J Brahmer, M Reck, KJ O'Byrne, WJ Geese, G Green, H Chang, J Szustakowski, P Bhagavatheeswaran, D Healey, Y Fu, F Nathan and L Paz-Ares
Abstract
Background Nivolumab plus ipilimumab showed promising efficacy for the treatment of non-small-cell lung cancer (NSCLC) in a phase 1 trial, and tumor mutational burden has emerged as a potential biomarker of benefit. In this part of an open-label, multipart, phase 3 trial, we examined progression-free survival with nivolumab plus ipilimumab versus chemotherapy among patients with a high tumor mutational burden (≥10 mutations per megabase). Methods We enrolled patients with stage IV or recurrent NSCLC that was not previously treated with chemotherapy. Those with a level of tumor programmed death ligand 1 (PD-L1) expression of at least 1% were randomly assigned, in a 1:1:1 ratio, to receive nivolumab plus ipilimumab, nivolumab monotherapy, or chemotherapy; those with a tumor PD-L1 expression level of less than 1% were randomly assigned, in a 1:1:1 ratio, to receive nivolumab plus ipilimumab, nivolumab plus chemotherapy, or chemotherapy. Tumor mutational burden was determined by the FoundationOne CDx assay. Results Progression-free survival among patients with a high tumor mutational burden was significantly longer with nivolumab plus ipilimumab than with chemotherapy. The 1-year progression-free survival rate was 42.6% with nivolumab plus ipilimumab versus 13.2% with chemotherapy, and the median progression-free survival was 7.2 months (95% confidence interval [CI], 5.5 to 13.2) versus 5.5 months (95% CI, 4.4 to 5.8) (hazard ratio for disease progression or death, 0.58; 97.5% CI, 0.41 to 0.81; P<0.001). The objective response rate was 45.3% with nivolumab plus ipilimumab and 26.9% with chemotherapy. The benefit of nivolumab plus ipilimumab over chemotherapy was broadly consistent within subgroups, including patients with a PD-L1 expression level of at least 1% and those with a level of less than 1%. The rate of grade 3 or 4 treatment-related adverse events was 31.2% with nivolumab plus ipilimumab and 36.1% with chemotherapy. Conclusions Progression-free survival was significantly longer with first-line nivolumab plus ipilimumab than with chemotherapy among patients with NSCLC and a high tumor mutational burden, irrespective of PD-L1 expression level. The results validate the benefit of nivolumab plus ipilimumab in NSCLC and the role of tumor mutational burden as a biomarker for patient selection. (Funded by Bristol-Myers Squibb and Ono Pharmaceutical; CheckMate 227 ClinicalTrials.gov number, NCT02477826 .).
Tweets*
484
Facebook likes*
9
Reddit*
0
News coverage*
30
Blogs*
4
SC clicks
3
Concepts
Epidemiology, Clinical trial, Adenocarcinoma, Non-small cell lung carcinoma, Paclitaxel, Bristol-Myers Squibb, Lung cancer, Cancer
MeSH headings
-
comments powered by Disqus

* Data courtesy of Altmetric.com